|
시장보고서
상품코드
2060324
심장 마커 검사 시장 예측(-2031년) : 제품별, 기술별, 적응증별, 바이오마커 유형별, 검사 시점별, 어세이 형식별, 최종사용자별, 지역별Cardiac Marker Testing Market by Product, Biomarker (Troponin, CK-MB, BNP, hs-CRP, Myoglobin), Technology (Chemiluminescence, ELISA), Indication (MI, CHF, Atherosclerosis), Assay Format (Singleplex, Multiplex), Point of Testing - Global Forecast to 2031 |
||||||
심장 마커 검사 시장 규모는 2025년에 약 50억 7,000만 달러, 2026년에 55억 4,000만 달러로 추계되고 있으며, 2031년까지 90억 6,000만 달러에 달하며, 10.3%의 성장률을 보일 것으로 예측됩니다.
시장은 꾸준히 성장하고 있으며, 병원과 진단 검사 기관들은 질병의 조기 발견과 정확한 진단, 그리고 환자의 예후 개선에 주력하고 있습니다.
| 조사 범위 | |
|---|---|
| 조사 대상 기간 | 2026-2031년 |
| 기준연도 | 2025년 |
| 예측 기간 | 2026-2031년 |
| 대상 단위 | 금액(10억 달러) |
| 부문 | 제품별, 기술별, 적응증별, 바이오마커 유형별, 검사 시점별, 어세이 형식별, 최종사용자별, 지역별 |
| 대상 지역 | 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카 |
심혈관 질환이 점점 더 복잡해지고 있는 점과 정부 기관의 정확한 진단 결과 및 품질관리에 대한 요구가 높아지고 있는 점도 전 세계에서 심장 마커 검사 솔루션에 대한 수요를 견인하고 있습니다.
“시약·키트 부문은 예측 기간 중 가장 높은 연평균 성장률(CAGR)을 보일 것으로 전망됩니다. '
이 부문의 성장은 검사마다 필요한 심장 마커용 키트 및 시약에 대한 지속적인 수요에 주로 힘입고 있습니다. 또한 심혈관 질환의 유병률도 증가하고 있으며, 그 결과 이러한 질환으로 인한 입원률도 증가하고 있습니다. 이로 인해 심장 마커 검사용 키트 및 시약에 대한 수요가 더욱 증가하고 있습니다.
“기술별로는 2026년에 면역측정 부문이 심장 마커 검사 시장에서 가장 큰 점유율을 차지할 것으로 예측됩니다. ” '
면역측정 부문이 시장을 주도하고 있는 이유는 병원 검사실, 참조 실험실 및 학술기관들이 심장 바이오마커 검출에 있으며, 높은 민감도, 특이도 및 신뢰성을 제공하는 면역측정법에 기반한 검사를 채택하고 있기 때문입니다. 면역측정법에 기반한 검사는 심근경색 및 관련 질환을 신속하고 정확하게 진단할 수 있으므로 일상적인 심장 검사에서 의료진이 가장 선호하는 기술로 자리 잡고 있습니다. 면역측정 기술에 대한 꾸준한 수요는 심혈관 질환의 발생률 증가와 조기 발견 및 관리에 대한 중요성이 부각된 데 기인합니다.
“지역별로 보면 아시아·태평양 지역이 심장 마커 검사 시장에서 가장 높은 성장률을 기록할 것으로 예상됩니다. ” '
해당 지역에서는 의료 인프라 확충, 의료비 증가, 병원 및 진단 시설의 현대화 등이 진행되는 등 몇 가지 주요 요인으로 인해 급속한 성장이 나타나고 있습니다. 또한 심혈관 질환 사례의 증가, 시행되는 검사 건수의 증가, 진단 검사실 및 제약 기업의 확대 역시 아시아태평양의 심장 마커 검사 시장 성장을 지원하고 있습니다.
심장 마커 검사 시장의 주요 기업은 F. Hoffmann-La Roche AG(스위스), Abbott Laboratories(미국), Siemens Healthineers AG(독일), Danaher Corporation(미국), Bio-Rad Laboratories, Inc.(미국), Biomerieux SA(프랑스), Becton, Dickinson and Company(미국), Thermo Fisher Scientific(미국), Diasorin SPA(이탈리아), Revvity(미국), Tosho Corporation(일본), 그리고 Quidel Corporation(미국)입니다.
조사 범위:
본 조사 보고서에서는 심장 마커 검사 시장을 제품(시약·키트, 기기), 기술(면역측정법, 임상화학), 적응증(심근경색, 울혈성심부전, 급성 관상동맥 증후군, 죽상동맥경화증, 허혈), 바이오마커 유형(트로포닌 I 및 T, 크레아티닌 키나제-MB, 뇌성 나트륨 이뇨 펩티드, 미오글로빈, 고감도 C-반응성 단백질, 호모시스테인, 기타 심장 바이오마커), 검사 시점(임상 검사, PoC 검사), 분석 방식(싱글플렉스 분석, 멀티플렉스 분석), 최종사용자(검사 기관, 학술기관, 현장 진단) 및 지역(북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카)입니다. 이 보고서의 범위는 심장 마커 검사 시장의 성장에 영향을 미치는 주요 요인(촉진요인, 억제요인, 기회, 과제 등)에 관한 상세한 정보를 포괄하고 있습니다. 주요 업계 기업에 대한 상세한 분석을 통해 각 기업의 사업 개요, 솔루션, 파트너십, 제휴, 사업 확장, 계약, 제품 출시와 같은 주요 전략은 물론, 심장 마커 검사 시장의 최근 동향에 대한 인사이트를 제공합니다. 이 보고서에서는 심장 마커 검사 시장의 생태계 내에서 신생 스타트업 기업의 경쟁 분석도 제공하고 있습니다.
이 보고서를 구매해야 하는 이유:
이 보고서는 심장 마커 검사 시장 전체 및 그 하위 부문의 매출에 대한 가장 정확한 추정치를 제공함으로써, 시장 선도 기업과 신규 진입 기업을 지원합니다. 이 보고서는 이해관계자들이 경쟁 구도를 이해하고, 더 심층 인사이트를 얻어 자사의 비즈니스를 적절히 포지셔닝하며, 적절한 시장 진입 전략을 수립하는 데 도움이 됩니다. 또한 이 보고서는 이해관계자들이 시장 동향을 파악할 수 있도록 지원하며, 주요 시장 촉진요인 및 과제에 관한 정보를 제공합니다.
이 보고서에서는 다음 사항에 대한 인사이트를 제공합니다. :
- 주요 촉진요인(심혈관 질환 유병률 상승, 고령 인구 증가 및 이에 따른 전 세계 심장 질환 증가, 새로운 심장 바이오마커 식별을 위한 임상 연구 증가, PoC 검사에 대한 수요 증가), 제약 요인(검체 채취 및 보존과 관련된 기술적 과제, 불리한 규제 절차, 제한적인 보험 급여 구조), 기회(심혈관 질환을 위한 새로운 심장 바이오마커에 대한 진행 중인 연구, 신흥 시장) 및 과제(바이오마커 분석법 검증과 관련된 과제)에 대해 분석하여, 심장 마커 검사 시장의 성장에 영향을 미치는 요인을 밝히고 있습니다.
- 제품 개발/혁신: 심장 마커 검사 시장의 향후 기술, 연구개발 활동 및 신제품 출시에 대한 상세 인사이트.
- 시장 개발: 수익성이 높은 시장에 대한 포괄적인 정보 - 이 보고서에서는 다양한 지역의 심장 마커 검사 시장을 분석하고 있습니다.
- 시장의 다각화: 심장 마커 검사 시장의 신제품, 미개발 지역, 최근 동향 및 투자에 관한 포괄적인 정보
경쟁사 분석: Hoffmann-La Roche AG(스위스), Abbott Laboratories(미국), Siemens Healthineers A(독일), Danaher Corporation(미국) 등 주요 기업의 시장 점유율, 성장 전략, 제품 라인업에 대한 상세한 평가.
자주 묻는 질문
목차
제1장 서론
제2장 개요
제3장 주요 인사이트
제4장 시장 개요
제5장 업계 동향
제6장 기술 진보, AI별 영향, 특허, 혁신, 향후 응용
제7장 지속가능성과 규제 상황
제8장 고객 상황과 구매 행동
제9장 심장 마커 검사 시장(제품별)
제10장 심장 마커 검사 시장(기술별)
제11장 심장 마커 검사 시장(적응증별)
제12장 심장 마커 검사 시장(바이오마커 유형별)
제13장 심장 마커 검사 시장의 수량 분석(바이오마커 유형별, 검사 건수)
제14장 심장 마커 검사 시장(검사 시점별)
제15장 심장 마커 검사 시장(어세이 형식별)
제16장 심장 마커 검사 시장(최종사용자별)
제17장 심장 마커 검사 시장(지역별)
제18장 경쟁 구도
제19장 기업 개요
제20장 조사 방법
제21장 부록
KSA 26.06.24The market for cardiac marker testing is valued at around USD 5.07 billion in 2025, USD 5.54 billion in 2026, and is forecast to reach USD 9.06 billion by 2031, representing a growth of 10.3%. The market is growing steadily, and the focus of hospitals and diagnostic laboratories is on early detection and accurate diagnosis of diseases, as well as on improving patient outcomes.
| Scope of the Report | |
|---|---|
| Years Considered for the Study | 2026-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD billion) |
| Segments | Product, Technology, Indication, Biomarker Type, Point Of Testing, Assay Format, End User |
| Regions covered | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
The increasing complexity of cardiovascular diseases and the need for accurate diagnostic results and quality control by government agencies are also driving global demand for cardiac marker testing solutions.
"The reagents & kits segment is predicted to showcase the highest CAGR during the forecast period."
The segment's growth is mainly driven by recurring demand for cardiac marker kits & reagents, which are required for every test. The prevalence rate for cardiovascular diseases is also on the rise, resulting in an increased hospitalization rate for such diseases. This, in turn, is fueling the demand for cardiac marker testing kits & reagents.
"The immunoassay segment is projected to hold the largest share of the cardiac marker testing market in 2026, by technology."
The immunoassay segment leads the market because hospital labs, reference labs, and academic institutions have adopted immunoassay-based testing, which offers higher sensitivity, specificity, and reliability for detecting cardiac biomarkers. It is the most preferred technology among healthcare providers for routine cardiac testing because immunoassay-based tests enable quick, accurate detection of myocardial infarction and related conditions. The consistent demand for immunoassay technology can be attributed to the rising incidence of cardiovascular diseases and the emphasis on early detection and management.
"Asia Pacific is expected to register the fastest growth rate in the cardiac marker testing market, by region."
The region is witnessing a growth spurt due to several key factors, including increased healthcare infrastructure, increased healthcare expenditure, and greater modernization of hospital and diagnostic facilities. In addition, rising cases of cardiovascular disease, increasing numbers of procedures performed, and growth in diagnostic labs and pharmaceutical companies are also driving growth in the cardiac marker testing market in the Asia Pacific region.
The break-up of the profile of primary participants in the cardiac marker testing market:
- By Company Type: Tier 1 - 26%, Tier 2 - 44%, and Tier - 30%
- By Designation: C-level - 30%, D-level - 34%, and Others - 36%
- By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Middle East & Africa- 4%
The key players in the cardiac marker testing market are F.Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), Siemens Healthineers AG (Germany), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), Biomerieux SA (France), Becton, Dickinson and Company (US), Thermo Fisher Scientific (US), Diasorin SPA (Italy), Revvity (US), Tosho Corporation (Japan), and Quidel Corporation (US).
Research Coverage:
This research report categorizes the cardiac marker testing market by product (Reagents & Kits, Instruments), technology (Immunoassay, Clinical Chemistry), indication (Myocardial Infraction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, Ischemia), biomarker type (Troponin I & T, Creatinine Kinase-MB, Brain Natriuretic Peptide, Myoglobin, High-Sensitivity C-Reactive Protein, Homocysteine, Other Cardiac Biomarkers), point of testing (Lab Test, PoC Test), assay format (Singleplex Assay, Multiplex Assay), end user (Laboratory Testing Facilities, Academic Institutes, Point-of-Care Testing), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges, influencing the growth of the cardiac marker testing market. A detailed analysis of the key industry players has been conducted to provide insights into their business overviews, solutions, key strategies such as partnerships, collaborations, expansions, agreements, product launches, and recent developments in the cardiac marker testing market. This report provides a competitive analysis of emerging startups in the cardiac marker testing market ecosystem.
Reasons to buy this report:
The report will help market leaders and new entrants with information on the closest approximations of revenue numbers for the overall cardiac marker testing market and its subsegments. This report will help stakeholders understand the competitive landscape and gain deeper insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
- Analysis of key drivers (rising prevalence of cardiovascular diseases, increasing geriatric population and subsequent rise in heart conditions worldwide, rising clinical studies for identification of novel cardiac biomarkers, growing demand for PoC testing), restraints (technical issues related to sample collection and storage, unfavorable regulatory processes and limited reimbursement structure), opportunities (ongoing research on novel cardiac biomarkers for cardiovascular diseases, emerging markets), and challenges (challenges associated with biomarker assay validation) influencing the growth of the cardiac marker testing market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the cardiac marker testing market.
- Market Development: Comprehensive information about lucrative markets - the report analyzes the cardiac marker testing market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cardiac marker testing market
Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like F.Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), Siemens Healthineers AG (Germany), and Danaher Corporation (US).
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
- 1.3.1 MARKETS COVERED & REGIONAL SCOPE
- 1.3.2 INCLUSIONS & EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.4 CURRENCY CONSIDERED
- 1.5 STAKEHOLDERS
- 1.6 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
- 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS
- 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS & STRATEGIC DEVELOPMENTS
- 2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH
- 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
- 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
- 3.1 CARDIAC MARKER TESTING MARKET OVERVIEW
- 3.2 CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2026 VS. 2031
- 3.3 CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2026 VS. 2031
- 3.4 CARDIAC MARKER TESTING MARKET, BY INDICATION, 2026 VS. 2031
- 3.5 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2026 VS. 2031
- 3.6 CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2026 VS. 2031
- 3.7 CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2026 VS. 2031
- 3.8 CARDIAC MARKER TESTING MARKET, BY END USER, 2026 VS. 2031
- 3.9 CARDIAC MARKER TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4 MARKET OVERVIEW
- 4.1 INTRODUCTION
- 4.2 MARKET DYNAMICS
- 4.2.1 DRIVERS
- 4.2.1.1 Rising prevalence of cardiovascular diseases
- 4.2.1.2 Increasing geriatric population and subsequent rise in heart conditions worldwide
- 4.2.1.3 Rising clinical studies for identification of novel cardiac biomarkers
- 4.2.1.4 Growing demand for PoC testing
- 4.2.2 RESTRAINTS
- 4.2.2.1 Technical issues related to sample collection and storage
- 4.2.2.2 Unfavorable regulatory processes and limited reimbursement structure
- 4.2.3 OPPORTUNITIES
- 4.2.3.1 Ongoing research on novel cardiac biomarkers for cardiovascular diseases
- 4.2.3.2 Emerging markets
- 4.2.4 CHALLENGES
- 4.2.4.1 Challenges associated with biomarker assay validation
- 4.2.1 DRIVERS
- 4.3 UNMET NEEDS & WHITE SPACES
- 4.3.1 UNMET NEEDS IN CARDIAC MARKER TESTING MARKET
- 4.3.2 WHITE SPACE OPPORTUNITIES
- 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
- 4.4.1 INTERCONNECTED MARKETS
- 4.4.2 CROSS-SECTOR OPPORTUNITIES
- 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
- 4.5.1 KEY MOVES & STRATEGIC FOCUS
5 INDUSTRY TRENDS
- 5.1 PORTER'S FIVE FORCES ANALYSIS
- 5.1.1 THREAT OF NEW ENTRANTS
- 5.1.2 THREAT OF SUBSTITUTES
- 5.1.3 BARGAINING POWER OF BUYERS
- 5.1.4 BARGAINING POWER OF SUPPLIERS
- 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.2 MACROECONOMIC INDICATORS
- 5.2.1 INTRODUCTION
- 5.2.2 GDP TRENDS & FORECAST
- 5.3 SUPPLY CHAIN ANALYSIS
- 5.4 VALUE CHAIN ANALYSIS
- 5.5 ECOSYSTEM ANALYSIS
- 5.6 PRICING ANALYSIS
- 5.6.1 AVERAGE SELLING PRICE OF CARDIAC MARKER TESTING PRODUCTS, BY TYPE, 2024-2026
- 5.6.2 AVERAGE SELLING PRICE OF CARDIAC MARKER TESTING PRODUCTS, BY KEY PLAYER, 2024-2026
- 5.6.3 AVERAGE SELLING PRICE OF CARDIAC MARKER TESTING PRODUCTS, BY REGION, 2024-2026
- 5.7 TRADE ANALYSIS
- 5.7.1 IMPORT SCENARIO (HS CODE 3822)
- 5.7.2 EXPORT SCENARIO (HS CODE 3822)
- 5.8 KEY CONFERENCES & EVENTS, 2026-2027
- 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
- 5.10 INVESTMENT & FUNDING SCENARIO
- 5.11 CASE STUDY ANALYSIS
- 5.11.1 CASE STUDY 1: IMPLEMENTATION OF HIGH-SENSITIVITY TROPONIN (HS-CTN) ASSAYS FOR RAPID MYOCARDIAL INFARCTION DIAGNOSIS
- 5.11.2 CASE STUDY 2: USE OF BNP/NT-PROBNP TESTING FOR HEART FAILURE DIAGNOSIS AND MANAGEMENT
- 5.11.3 CASE STUDY 3: USE OF HIGH-SENSITIVITY TROPONIN FOR LONG-TERM CARDIOVASCULAR RISK PREDICTION IN GENERAL POPULATION
- 5.12 IMPACT OF 2025 US TARIFFS ON CARDIAC MARKER TESTING MARKET
- 5.12.1 INTRODUCTION
- 5.12.2 KEY TARIFF RATES
- 5.12.3 PRICE IMPACT ANALYSIS
- 5.12.4 IMPACT ON REGION
- 5.12.4.1 North America
- 5.12.4.2 Europe
- 5.12.4.3 Asia Pacific
- 5.12.5 IMPACT ON END-USE INDUSTRIES
- 5.12.5.1 Hospital laboratories
- 5.12.5.2 Reference laboratories
- 5.12.5.3 Contract testing laboratories
- 5.12.5.4 Academic institutes
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
- 6.1 KEY EMERGING TECHNOLOGIES
- 6.1.1 CHEMILUMINESCENCE IMMUNOASSAYS (CLIA)
- 6.1.2 IMMUNOFLUORESCENCE ASSAYS (IFA)
- 6.1.3 ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA)
- 6.1.4 LATERAL FLOW ASSAYS
- 6.2 COMPLEMENTARY TECHNOLOGIES
- 6.2.1 POC IMMUNOANALYZERS
- 6.2.2 DIGITAL IMMUNOASSAY PLATFORMS
- 6.3 TECHNOLOGY/PRODUCT ROADMAP
- 6.4 PATENT ANALYSIS
- 6.4.1 LIST OF MAJOR PATENTS
- 6.4.2 LIST OF KEY PATENTS
- 6.5 FUTURE APPLICATIONS
- 6.6 IMPACT OF AI/GENERATIVE AI ON CARDIAC MARKER TESTING MARKET
- 6.6.1 INTRODUCTION
- 6.6.2 TOP USE CASES & MARKET POTENTIAL
- 6.6.3 KEY COMPANIES IMPLEMENTING AI
- 6.6.4 FUTURE OF AI
7 SUSTAINABILITY & REGULATORY LANDSCAPE
- 7.1 REGIONAL REGULATIONS & COMPLIANCE
- 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 7.2 SUSTAINABILITY INITIATIVES
- 7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN CARDIAC MARKER TESTING PRODUCTS
- 7.2.1.1 Eco-friendly Initiatives
- 7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN CARDIAC MARKER TESTING PRODUCTS
- 7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
- 8.1 DECISION-MAKING PROCESS
- 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
- 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 8.2.2 BUYING CRITERIA
- 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
- 8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
- 8.5 MARKET PROFITABILITY
- 8.5.1 REVENUE POTENTIAL
- 8.5.2 COST DYNAMICS
- 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS
9 CARDIAC MARKER TESTING MARKET, BY PRODUCT
- 9.1 INTRODUCTION
- 9.2 REAGENTS & KITS
- 9.2.1 RISING VOLUME OF DIAGNOSTIC TESTS TO DRIVE DEMAND FOR REAGENTS & KITS
- 9.3 INSTRUMENTS
- 9.3.1 EXPANDING DIAGNOSTIC INFRASTRUCTURE TO DRIVE MARKET GROWTH
10 CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY
- 10.1 INTRODUCTION
- 10.2 IMMUN0ASSAYS
- 10.2.1 CHEMILUMINESCENCE
- 10.2.1.1 High sensitivity, wide linear range, and good specificity to aid market growth
- 10.2.2 IMMUNOFLUORESCENCE
- 10.2.2.1 Advancements in fluorescence technologies to drive immunofluorescence adoption
- 10.2.3 LATERAL FLOW IMMUNOASSAYS
- 10.2.3.1 Increasing use in point-of-care settings to propel adoption
- 10.2.4 ELISA
- 10.2.4.1 Long shelf life and ease of use to propel growth
- 10.2.1 CHEMILUMINESCENCE
- 10.3 CLINICAL CHEMISTRY
- 10.3.1 COST-EFFECTIVENESS AND HIGH-THROUGHPUT TESTING TO SUSTAIN GROWTH IN CLINICAL CHEMISTRY MARKET
11 CARDIAC MARKER TESTING MARKET, BY INDICATION
- 11.1 INTRODUCTION
- 11.2 MYOCARDIAL INFARCTION
- 11.2.1 RISING MYOCARDIAL INFARCTION BURDEN AND NEED FOR EARLY DIAGNOSIS TO DRIVE CARDIAC MARKER TESTING DEMAND
- 11.3 CONGESTIVE HEART FAILURE
- 11.3.1 INCREASING USE OF MULTIMARKER TESTING TO SUPPORT MARKET GROWTH
- 11.4 ACUTE CORONARY SYNDROME
- 11.4.1 INCREASING INCIDENCE OF RISK FACTORS ASSOCIATED WITH ACS TO DRIVE ADOPTION OF CARDIAC MARKERS
- 11.5 ATHEROSCLEROSIS
- 11.5.1 HIGH PREVALENCE OF ATHEROSCLEROSIS TO DRIVE MARKET
- 11.6 ISCHEMIA
- 11.6.1 INCREASE IN CARDIAC ISCHEMIA TO BOOST DEMAND FOR CARDIAC MARKER TESTS
12 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE
- 12.1 INTRODUCTION
- 12.2 TROPONIN I & T
- 12.2.1 HIGH SENSITIVITY AND SPECIFICITY IN DETECTION OF CVD TO DRIVE MARKET
- 12.3 CREATININE KINASE-MB
- 12.3.1 POOR SPECIFICITY AND BRIEF ELEVATION DURATION TO HAMPER MARKET GROWTH
- 12.4 BRAIN NATRIURETIC PEPTIDE
- 12.4.1 USE OF BNP WITH OTHER CARDIAC MARKERS TO ENHANCE UTILIZATION
- 12.5 MYOGLOBIN
- 12.5.1 GROWING USE TO ASSESS PATIENTS WITH CHEST PAIN IN EMERGENCY DEPARTMENT SETTINGS TO BOOST GROWTH
- 12.6 HOMOCYSTEINE
- 12.6.1 RISK STRATIFICATION AND LONG-TERM CARDIOVASCULAR RISK ASSESSMENT TO DRIVE MARKET GROWTH
- 12.7 HIGH-SENSITIVITY C-REACTIVE PROTEIN
- 12.7.1 INCREASING INCIDENCE OF CARDIOVASCULAR DISEASES TO PROPEL ADOPTION
- 12.8 OTHER CARDIAC BIOMARKERS
13 CARDIAC MARKER TESTING MARKET VOLUME ANALYSIS, BY BIOMARKER TYPE (NUMBER OF TESTS)
14 CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING
- 14.1 INTRODUCTION
- 14.2 LAB TESTS
- 14.2.1 HIGH-SENSITIVITY, AUTOMATION, AND FLEXIBLE PROCUREMENT MODELS TO DRIVE LAB-BASED TESTING DOMINANCE
- 14.3 POC TESTS
- 14.3.1 RISING DEMAND FOR DECENTRALIZED HEALTHCARE SERVICES TO DRIVE MARKET
15 CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT
- 15.1 INTRODUCTION
- 15.2 SINGLEPLEX ASSAYS
- 15.2.1 HIGH ACCURACY AND OPERATIONAL SIMPLICITY TO SUSTAIN SINGLEPLEX ASSAY DOMINANCE
- 15.3 MULTIPLEX ASSAYS
- 15.3.1 COMPREHENSIVE MULTI-BIOMARKER DETECTION AND RAPID DIAGNOSIS TO DRIVE MULTIPLEX ASSAY GROWTH
16 CARDIAC MARKER TESTING MARKET, BY END USER
- 16.1 INTRODUCTION
- 16.2 LABORATORY TESTING FACILITIES
- 16.2.1 HOSPITAL LABORATORIES
- 16.2.1.1 Growing focus on healthcare system to stimulate growth
- 16.2.2 REFERENCE LABORATORIES
- 16.2.2.1 Rising outsourcing and advanced testing capabilities to position reference laboratories as key growth drivers
- 16.2.3 CONTRACT TESTING LABORATORIES
- 16.2.3.1 Outsourced expertise and scalable testing capabilities to boost role of contract laboratories
- 16.2.1 HOSPITAL LABORATORIES
- 16.3 ACADEMIC INSTITUTES
- 16.3.1 CONTINUOUS RESEARCH & DEVELOPMENT OF NOVEL BIOMARKERS TO DRIVE MARKET
- 16.4 POINT-OF-CARE TESTING
- 16.4.1 EARLY DETECTION AND LOWER TURNAROUND TIME TO BOOST MARKET
17 CARDIAC MARKER TESTING MARKET, BY REGION
- 17.1 INTRODUCTION
- 17.2 NORTH AMERICA
- 17.2.1 US
- 17.2.1.1 Growing support from NIH for development of novel cardiac biomarkers to drive market
- 17.2.2 CANADA
- 17.2.2.1 Government initiatives to support market growth
- 17.2.1 US
- 17.3 EUROPE
- 17.3.1 GERMANY
- 17.3.1.1 Stringent regulations for food, pharmaceutical, and medical device industries to fuel growth
- 17.3.2 UK
- 17.3.2.1 Increasing cardiovascular patient volume to spur growth
- 17.3.3 FRANCE
- 17.3.3.1 Highly advanced and well-established healthcare system to drive demand for market
- 17.3.4 ITALY
- 17.3.4.1 Growing geriatric population and improved life expectancy to support market growth
- 17.3.5 SPAIN
- 17.3.5.1 Government efforts to improve health infrastructure to fuel demand
- 17.3.6 REST OF EUROPE
- 17.3.1 GERMANY
- 17.4 ASIA PACIFIC
- 17.4.1 JAPAN
- 17.4.1.1 Growing geriatric population and increasing incidence of chronic diseases to drive market
- 17.4.2 CHINA
- 17.4.2.1 Rising number of hospitals and increasing healthcare expenditure to boost adoption
- 17.4.3 INDIA
- 17.4.3.1 Infrastructural improvements to support growth
- 17.4.4 AUSTRALIA
- 17.4.4.1 Higher government healthcare expenditure to support market growth
- 17.4.5 SOUTH KOREA
- 17.4.5.1 Country's fast-aging demographic to drive market
- 17.4.6 REST OF ASIA PACIFIC
- 17.4.1 JAPAN
- 17.5 LATIN AMERICA
- 17.5.1 BRAZIL
- 17.5.1.1 Rising government support to boost adoption of market
- 17.5.2 MEXICO
- 17.5.2.1 Rising geriatric population to support market growth
- 17.5.3 REST OF LATIN AMERICA
- 17.5.1 BRAZIL
- 17.6 MIDDLE EAST & AFRICA
18 COMPETITIVE LANDSCAPE
- 18.1 INTRODUCTION
- 18.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 18.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN CARDIAC MARKER TESTING MARKET
- 18.3 REVENUE ANALYSIS, 2023-2025
- 18.4 MARKET SHARE ANALYSIS, 2025
- 18.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025
- 18.4.2 US MARKET SHARE ANALYSIS, 2025
- 18.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
- 18.5.1 STARS
- 18.5.2 EMERGING LEADERS
- 18.5.3 PERVASIVE PLAYERS
- 18.5.4 PARTICIPANTS
- 18.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
- 18.5.5.1 Company footprint
- 18.5.5.2 Region footprint
- 18.5.5.3 Product footprint
- 18.5.5.4 Technology footprint
- 18.5.5.5 Point of testing footprint
- 18.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
- 18.6.1 PROGRESSIVE COMPANIES
- 18.6.2 RESPONSIVE COMPANIES
- 18.6.3 DYNAMIC COMPANIES
- 18.6.4 STARTING BLOCKS
- 18.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
- 18.6.5.1 Detailed list of key startups/SMEs
- 18.6.5.2 Competitive benchmarking of startups/SMEs (1/2)
- 18.6.5.3 Competitive benchmarking of startups/SMEs (2/2)
- 18.7 COMPANY VALUATION & FINANCIAL METRICS
- 18.7.1 FINANCIAL METRICS
- 18.7.2 COMPANY VALUATION
- 18.8 BRAND/PRODUCT COMPARISON
- 18.9 COMPETITIVE SCENARIO
- 18.9.1 PRODUCT APPROVALS
- 18.9.2 DEALS
19 COMPANY PROFILES
- 19.1 KEY PLAYERS
- 19.1.1 F. HOFFMANN-LA ROCHE AG
- 19.1.1.1 Business overview
- 19.1.1.2 Products offered
- 19.1.1.3 Recent developments
- 19.1.1.3.1 Product approvals
- 19.1.1.3.2 Deals
- 19.1.1.4 MnM view
- 19.1.1.4.1 Key strengths
- 19.1.1.4.2 Strategic choices
- 19.1.1.4.3 Weaknesses & competitive threats
- 19.1.2 ABBOTT LABORATORIES
- 19.1.2.1 Business overview
- 19.1.2.2 Products offered
- 19.1.2.3 MnM view
- 19.1.2.3.1 Key strengths
- 19.1.2.3.2 Strategic choices
- 19.1.2.3.3 Weaknesses & competitive threats
- 19.1.3 DANAHER CORPORATION
- 19.1.3.1 Business overview
- 19.1.3.2 Products offered
- 19.1.3.3 MnM view
- 19.1.3.3.1 Key strengths
- 19.1.3.3.2 Strategic choices
- 19.1.3.3.3 Weaknesses & competitive threats
- 19.1.4 SIEMENS HEALTHINEERS AG
- 19.1.4.1 Business overview
- 19.1.4.2 Products offered
- 19.1.4.3 MnM view
- 19.1.4.3.1 Key strengths
- 19.1.4.3.2 Strategic choices
- 19.1.4.3.3 Weaknesses & competitive threats
- 19.1.5 THERMO FISHER SCIENTIFIC
- 19.1.5.1 Business overview
- 19.1.5.2 Products offered
- 19.1.5.3 MnM view
- 19.1.5.3.1 Key strengths
- 19.1.5.3.2 Strategic choices
- 19.1.5.3.3 Weaknesses & competitive threats
- 19.1.6 BIO-RAD LABORATORIES
- 19.1.6.1 Business overview
- 19.1.6.2 Products offered
- 19.1.7 BIOMERIEUX SA
- 19.1.7.1 Business overview
- 19.1.7.2 Products offered
- 19.1.7.3 Recent developments
- 19.1.7.3.1 Deals
- 19.1.8 BECTON, DICKINSON AND COMPANY
- 19.1.8.1 Business overview
- 19.1.8.2 Products offered
- 19.1.9 DIASORIN SPA
- 19.1.9.1 Business overview
- 19.1.9.2 Products offered
- 19.1.10 REVVITY
- 19.1.10.1 Business overview
- 19.1.10.2 Products offered
- 19.1.11 TOSOH CORPORATION
- 19.1.11.1 Business overview
- 19.1.11.2 Products offered
- 19.1.12 QUIDEL CORPORATION
- 19.1.12.1 Business overview
- 19.1.12.2 Products offered
- 19.1.12.3 Recent developments
- 19.1.12.3.1 Product approvals
- 19.1.12.3.2 Deals
- 19.1.1 F. HOFFMANN-LA ROCHE AG
- 19.2 OTHER PLAYERS
- 19.2.1 LSI MEDIENCE CORPORATION (PHC HOLDINGS CORPORATION)
- 19.2.2 RANDOX LABORATORIES
- 19.2.3 GUANGZHOU WONDFO BIOTECH CO., LTD.
- 19.2.4 BODITECH MED INC.
- 19.2.5 BTNX INC.
- 19.2.6 RESPONSE BIOMEDICAL
- 19.2.7 ALFA SCIENTIFIC DESIGNS, INC.
- 19.2.8 CTK BIOTECH
- 19.2.9 CREATIVE DIAGNOSTICS
- 19.2.10 LIFESIGN LLC
- 19.2.11 DIASYS DIAGNOSTIC SYSTEMS GMBH
- 19.2.12 ATLAS MEDICAL GMBH
- 19.2.13 GETEIN BIOTECH INC.
20 RESEARCH METHODOLOGY
- 20.1 RESEARCH DATA
- 20.1.1 SECONDARY DATA
- 20.1.1.1 List of secondary sources
- 20.1.1.2 Key data from secondary sources
- 20.1.2 PRIMARY DATA
- 20.1.2.1 List of primary sources
- 20.1.2.2 Key data from primary sources
- 20.1.2.3 Key industry insights
- 20.1.2.4 Breakdown of primary interviews
- 20.1.1 SECONDARY DATA
- 20.2 MARKET SIZE ESTIMATION
- 20.2.1 TOTAL MARKET SIZE: CARDIAC MARKER TESTING MARKET
- 20.2.2 BOTTOM-UP APPROACH
- 20.2.2.1 Approach 1: Revenue estimation of key players
- 20.2.2.2 Approach 2: Study of annual reports and investor presentations
- 20.2.2.3 Approach 3: Primary interviews
- 20.2.2.4 Growth forecast
- 20.2.2.5 CAGR projections
- 20.2.3 TOP-DOWN APPROACH
- 20.3 DATA TRIANGULATION
- 20.4 RESEARCH ASSUMPTIONS
- 20.4.1 STUDY-RELATED ASSUMPTIONS
- 20.4.2 GROWTH RATE ASSUMPTIONS
- 20.5 RESEARCH LIMITATIONS
- 20.6 RISK ASSESSMENT
21 APPENDIX
- 21.1 DISCUSSION GUIDE
- 21.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 21.3 CUSTOMIZATION OPTIONS
- 21.4 RELATED REPORTS
- 21.5 AUTHOR DETAILS
